Akeso, Inc. (HKEX: 9926.HK), a prominent biopharmaceutical innovator headquartered in Hong Kong, announced on November 3, 2025, that its first-in-class bispecific antibody therapy, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for the first-line treatment of triple-negative breast cancer (TNBC), has received its fourth Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) at China’s National Medical Products Administration (NMPA). This latest regulatory recognition is poised to expedite both the clinical development pathway and regulatory review for ivonescimab in this high unmet need oncology indication. The ongoing Phase III multicenter, randomized, double-blind clinical trial (HARMONi-BC1/AK112-308) for this combination is being conducted throughout China. This BTD signifies that regulatory authorities see substantial evidence that this therapy may offer significant clinical improvement over available therapies for Chinese patients with first-line TNBC, a notoriously difficult-to-treat and aggressive cancer subtype.

This is the fourth time that CDE has awarded BTD status to ivonescimab, reflecting its growing clinical promise across multiple major cancer indications. Previous designations have included approval for ivonescimab plus chemotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR-TKI therapy (now marketed and added to China’s National Reimbursement Drug List), approval for first-line PD-L1-positive locally advanced/metastatic NSCLC, and ongoing Phase III trials in ivonescimab with docetaxel for NSCLC patients who failed previous PD-1/L1 inhibitors and platinum-based therapy. These repeated milestones underscore both Akeso’s robust R&D engine and strong strategic positioning in China’s innovation-driven pharma sector.

The granting of BTD to ivonescimab for TNBC is particularly significant given the challenging nature of treating 'cold tumors' like triple-negative breast cancer, which lack standard therapeutic targets and have limited treatment options. The rapid regulatory review enabled by this status will accelerate time-to-market, create differentiated commercial opportunities and address urgent patient needs. Akeso's pipeline leadership is further confirmed by more than 14 Phase III clinical trials in progress worldwide for ivonescimab, including four pivotal international multicentre studies covering other solid tumors such as MSS/pMMR colorectal cancer (which represents 95% of colorectal cancer cases) and pancreatic cancer. The company currently has nearly 20 active Phase II studies across more than 10 additional indications, establishing an extensive clinical data foundation and facilitating global Phase III expansion.

From a business perspective, this BTD supports Akeso’s strategy to build out an integrated, end-to-end innovation and manufacturing platform (the ACE Platform and proprietary bi-specific antibody technology, Tetrabody), enhancing its competitive position in China’s rapidly maturing biopharma market. With over 50 innovative pipeline assets—including 15 bispecific/multispecific antibodies and bispecific ADCs—and seven new drugs already commercially available, Akeso is positioned for sustainable growth in both domestic and international markets. Its GMP-compliant manufacturing system and commercialization infrastructure are designed to scale rapidly as more of its pipeline approaches regulatory approval. The regulatory momentum seen with ivonescimab also makes Akeso an attractive potential partner for global licensing, technology transfer, contract manufacturing, and CRO/CMO collaboration in Asia-Pacific life sciences.

Looking ahead, Akeso’s ability to execute on global expansion will depend on successful navigation of international regulatory environments, effective technology transfer, and maintaining innovation among competitive pressures. Nevertheless, the company’s repeated success with BTD (including today’s announcement for TNBC), its robust late-stage R&D activity, and fully integrated commercialization strategies signal strong prospects for ongoing investment, strategic partnerships, and global licensing opportunities. In sum, today’s development both accelerates a potentially transformative therapy for cancer patients and illustrates the dynamic growth of innovative Chinese biopharma firms in the Asian and global pharmaceutical industry.